Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | PKMYT1 | Q99640 | 4/20 | 0.36 |
| ▸ | WEE1 | P30291 | 2/20 | 0.36 |
| ▸ | MYT1 | Q01538 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31307651 | 0.87 | POLB (0.48) | POLBTDP1SIRT3PKMYT1WEE1 | |
| SCHEMBL3357139 | 0.84 | SIRT3 (0.42) | POLBTDP1SIRT3PKMYT1WEE1 | |
| SCHEMBL128133 | 0.84 | SIRT3 (0.42) | POLBTDP1SIRT3PKMYT1WEE1 | |
| SCHEMBL27923877 | 0.82 | ERN1 (0.38) | POLBTDP1SIRT3PKMYT1WEE1 | |
| SCHEMBL27726519 | 0.81 | HAAO (0.40) | POLBTDP1SIRT3CA1CA2 | |
| SCHEMBL9419381 | 0.81 | GABRP (0.40) | POLBTDP1SIRT3ALDH1A1HPGD | |
| SCHEMBL27701114 | 0.79 | ALDH1A1 (0.43) | POLBPKMYT1WEE1MYT1MAPT | |
| SCHEMBL17829704 | 0.78 | POLB (0.41) | POLBTDP1SIRT3PKMYT1WEE1 | |
| SCHEMBL28762060 | 0.78 | ALDH1A1 (0.50) | POLBCA1CA2ALDH1A1GAA | |
| SCHEMBL1004338 | 0.77 | POLB (0.47) | POLBTDP1SIRT3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575617-A1 | USE OF TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT AND PERMEATION-ENHANCING BASE FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VARIOUS FORMS OF INFLAMMATORY DERMATOSIS | Dermatrends, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1572166-A1 | DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB, VALDECOXIB AND BENZOPYRAN DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1565169-A1 | DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB AND VALDECOXIB | Pharmacia Corporation (US) | 2005-08-24 | — | — | EP | claimed |
| EP-1558228-A1 | TOPICAL ADMINISTRATION OF BASIC ANTIFUNGAL COMPOSITIONS TO TREAT FUNGAL INFECTIONS OF THE NAILS | Dermatrends, Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| EP-1556008-A1 | USE OF BASES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DIFFERENT FORMS OF INFLAMMATORY DERMATOSIS | Dermatrends, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1429791-A4 | METHOD AND TOPICAL FORMULATION FOR TREATING SKIN CONDITIONS ASSOCIATED WITH AGING | DERMATRENDS INC (US) | 2005-01-05 | — | — | EP | claimed |
| US-6821523-B2 | APPLYING BASIC DRUGS TO SKINS FOR PROPHYLAXIS OF HUMAN PAPILLOMAVIRUS INFECTIONS; SKIN DISODERS | DERMATRENDS, INC. | 2004-11-23 | — | — | US | claimed |
| EP-1429791-A2 | METHOD AND TOPICAL FORMULATION FOR TREATING SKIN CONDITIONS ASSOCIATED WITH AGING | Dermatrends, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2004047814-A1 | DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB, VALDECOXIB AND BENZOPYRAN DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | claimed |
| WO-2004047815-A1 | DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB AND VALDECOXIB | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | claimed |
| US-20030072814-A1 | Topical pharmaceutical composition for the treatment of warts | DERMATRENDS, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003026680-A2 | METHOD AND TOPICAL FORMULATION FOR TREATING SKIN CONDITIONS ASSOCIATED WITH AGING | DERMATRENDS, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20030059450-A1 | Method and topical formulation for treating skin conditions associated with aging | MAIBACH HOWARD I (US) | 2003-03-27 | — | — | US | claimed |
| WO-2002096435-A2 | SKIN-PERMEABLE COMPOSITION COMPRISING A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR A MONOHYDRIC ALCOHOL | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | claimed |
| EP-0813879-B1 | Drug administration composition for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | claimed |
| US-20020041854-A1 | Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods | L'OREAL S.A. (FR) | 2002-04-11 | — | — | US | claimed |
| US-20020034480-A1 | Make-up compositions comprising a binder phase, and make-up methods | L'OREAL, S.A. (FR) | 2002-03-21 | — | — | US | claimed |
| EP-1155676-A2 | Composition for make-up or skin-care in a powdery form and containing a particular binder | L'OREAL (FR) | 2001-11-21 | — | — | EP | claimed |
| EP-0906093-A1 | ALPHA BLOCKERS (e.g. MOXISYLYTE AND/OR DERIVATIVES THEREOF) FOR TREATING ERECTILE DYSFUNCTION | Biotec Centre S.A. (FR) | 1999-04-07 | — | — | EP | claimed |
| WO-1997042946-A1 | ALPHA BLOCKERS (e.g. MOXISYLYTE AND/OR DERIVATIVES THEREOF) FOR TREATING ERECTILE DYSFUNCTION | BIOTEC CENTRE S.A. (FR) | 1997-11-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020034480-A1 | Make-up compositions comprising a binder phase, and make-up methods | TTR, GRN, MB | POLB 437/4885TDP1 969/4885SIRT3 2632/4885 |
| US-20020041854-A1 | Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods | CUTA, LAGE3, MITF | POLB 327/4885TDP1 2032/4885SIRT3 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.